Avacta has announced an update ahead of its AGM today. The key highlight is that dosing in the second cohort of the two weekly clinical test of AVA6000 (Arm 2 of Phase 1) has been successfully completed without dose limiting toxicities being observed and that dosing is now ongoing in cohort 3. That keeps the company on track to commence the dose expansion Phase 1b efficacy study in 2H24 when it also expects to present further data from the AVA6000 trial. In addition, Avacta has announced the formation of a Scientific Advisory Board to support the broader development of AVA6000 and the pre|CISION™ pipeline, a number of Board changes, and that net cash at 31st May was c£35m, sufficient to progress AVA6000 into Phase 2 clinical trials and develop the wider drug pipeline. Avacta plans to hold a Research and Development Spotlight Science Day in 4Q24 when it will provide more detail on the future of the pre|CISION™ platform.
![working](/images/WorkingLarge.gif)
26 Jun 2024
Avacta Group | AGM update – Good progress in Arm 2 testing
![](/images/orange-lock.png)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group | AGM update – Good progress in Arm 2 testing
Avacta Group PLC (AVCT:LON) | 65.5 4.4 11.5% | Mkt Cap: 235.2m
- Published:
26 Jun 2024 -
Author:
Colin Smith -
Pages:
4 -
Avacta has announced an update ahead of its AGM today. The key highlight is that dosing in the second cohort of the two weekly clinical test of AVA6000 (Arm 2 of Phase 1) has been successfully completed without dose limiting toxicities being observed and that dosing is now ongoing in cohort 3. That keeps the company on track to commence the dose expansion Phase 1b efficacy study in 2H24 when it also expects to present further data from the AVA6000 trial. In addition, Avacta has announced the formation of a Scientific Advisory Board to support the broader development of AVA6000 and the pre|CISION™ pipeline, a number of Board changes, and that net cash at 31st May was c£35m, sufficient to progress AVA6000 into Phase 2 clinical trials and develop the wider drug pipeline. Avacta plans to hold a Research and Development Spotlight Science Day in 4Q24 when it will provide more detail on the future of the pre|CISION™ platform.